Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.” The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number following the reverse stock split will be 114082 308.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
- Eterna Therapeutics Completes $6M Private Placement
- Eterna Therapeutics Increases Authorized Shares and Amends Bylaws
- Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025
- Ernexa Therapeutics establishes Texas subsidiary
- Ernexa Therapeutics presents data on cell therapy treatment at AACR meeting